Curium, in collaboration with nuclear cardiology leaders, announces immediate return of Thallous Chloride TI 201 Injection in the U.S. to support high-stakes cardiac imaging needs

RegulatoryapprovedThallous Chloride TI 201 InjectionPositive

AI Analysis

Summary

Curium announced the reintroduction of Thallous Chloride TI 201 Injection (Thallium-201) in the U.S., restoring access to a key nuclear cardiology imaging agent in collaboration with nuclear cardiology leaders.

Outcome Details

Reintroduction of Thallium-201 in the U.S. market

Importance:5/10

Sentiment:

0.60

nuclear cardiologyimaging agentmarket reintroductionregulatory approval

Read the original article

Published by GlobeNewswire Pharma on July 27, 2026 12:00 PM

Read Original